专利检索 ap:("THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health AND Human Services") AND inv:"Zhen Han" 第 1 页

1.

发明授权
Therapeutic antitumor combination of a TLR4 ligand with other treatments 有权

公开(公告)号：US11266746B2

公开(公告)日：2022-03-08

申请号：US16313454

申请日：2017-02-24

申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services

发明人： Joost J. Oppenheim , De Yang , Zhen Han , Joseph John Barchi, Jr. , Michael Bustin

IPC分类号： A61K47/69 , A61K9/51 , A61K39/395 , C07K16/28 , A61K31/664 , C07D215/00 , A61K45/06 , A61K38/17 , A61P35/00 , A61K9/00 , A61K31/4745 , A61K47/02 , B82Y5/00

摘要： Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.